On July 15, 2014, EPIRUS Biopharmaceuticals Inc., formerly known as Zalicus Inc. completed its merger with the former entity EPIRUS Biopharmaceuticals Inc. Pursuant to the terms of the Merger Agreement, effective immediately prior to the consummation of the Merger on July 15, 2014, Frank Haydu, Sally W. Crawford, Michael Kauffman and W. James O'Shea resigned from the company's board of directors. and J. Kevin Buchi, Geoffrey Duyk, Daotian Fu, Julie McHugh, Amit Munshi and Scott Rocklage were appointed as directors of the Company. Pursuant to the terms of the Merger Agreement, effective immediately after the consummation of the Merger on July 15, 2014, Mark H.N. Corrigan was terminated without cause from his position as President and Chief Executive Officer of the company, and Justin Renz was terminated without cause from his position as Executive Vice President, Chief Financial Officer, Treasurer and Secretary of the company.

Amit Munshi was appointed as the company's President and Chief Executive Officer and Thomas Shea was appointed as the company's Chief Financial Officer.